Erin D. Michos, MD, MHS, previews the American College of Cardiology 2024 Scientific Sessions, where four late-breaking clinical trials in the lipid field will be presented. The first trial, LIBerate-CVD, focuses on lerodalcibep (LIB003), a novel PCSK9 inhibitor, aiming to assess its efficacy in patients with established or high-risk cardiovascular disease (CVD). Lerodalcibep has shown promising results in reducing LDL and lipoprotein (a) levels. The second trial, BRIDGE-TIMI 73a, investigates olezarsen, a third-generation ApoC-III inhibitor, for patients with hypertriglyceridemia and high cardiovascular risk.
The SHASTA-2 trial assesses plozasiran, a small interfering RNA targeting ApoC-III, in patients with severe hypertriglyceridemia, showing preliminary reductions in triglycerides and non-HDL. Lastly, the AEGIS-II trial evaluates CSL112, a potential HDL-raising therapy that unfortunately did not meet its primary efficacy for reducing major adverse cardiovascular events (MACE) at 90 days, potentially marking the end of HDL-targeted therapeutics. These trials represent significant advancements and challenges in lipid management, addressing various aspects of cardiovascular risk reduction.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ACC 2024: Anticipating Advancements in Lipid Management - Medscape - Apr 01, 2024.
Comments